Despite the fact that targeted immunotherapy, such as anti-programmed death receptor-1/programmed death protein ligand-1 (PD-1/L1) monoclonal antibody (mAb) treatment, has improved efficacy and durability in multiple tumor types, the inhibition of a single immune checkpoint may not be enough to overcome immune suppression1,2. This evidence concerns the gene PDCD1 and neoplasm.